CRISPR Therapeutics CRSP
$39.10 +$0.17 (+0.44%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $39.50 +1.02%
Open$38.18
Prev close$38.93
Day range$38.15 – $40.17
Volume3.32M
Market cap$3.79B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$12.32M+1,325.1% YoY
Operating profit-$118.37M+10.4% YoY
Net profit-$111.44M-4.7% YoY
Diluted EPS-$1.15+1.7% YoY
Free cash flow-$89.27M-5.4% YoY
Operating cash flow-$89.68M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin-676.9%
Operating margin-2,221.7%
Net margin-1,955.7%
Return on equity-25.6%
Return on assets-19.0%
Return on invested capital-20.0%
Current ratio16.21
Liabilities / assets35.5%
Cash & investments$2.27B
Total debt$761.15M
Net cash (debt)$1.51B
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $12.67M | $10.18M | $1.46M | $3.51M | $864,000.00 |
| Total Operating Revenue | $12.32M | $10.00M | $1.00M | $0.00 | $0.00 |
| Cost of Revenue | $41.28M | $40.27M | $45.95M | $213.48M | $53.70M |
| Gross Profit | -$28.96M | -$30.27M | -$44.95M | -$213.48M | -$53.70M |
| Operating Expense | $89.41M | $84.52M | $85.30M | $354.84M | $101.06M |
| Selling and Admin Expenses | $17.87M | $17.55M | $17.18M | $73.54M | $18.40M |
| -General & Admin Expense | $17.87M | $17.55M | $17.18M | $73.54M | $18.40M |
| Research & Development | $71.89M | $67.15M | $68.57M | $284.81M | $83.53M |
| Other Operating Expenses | -$346,000.00 | -$181,000.00 | -$458,000.00 | -$3.51M | -$864,000.00 |
| Operating Profit | -$118.37M | -$114.80M | -$130.25M | -$568.32M | -$154.76M |
| Other Income (Expense) | $7.01M | $24.60M | $8.16M | -$9.65M | $24.77M |
| Special Income (Charges) | -$11.68M | -$2.47M | – | -$96.25M | $0.00 |
| -Less:Other Special Charges | $11.68M | $2.47M | – | $96.25M | $0.00 |
| Other Non-Operating Income (Expenses) | $18.68M | $27.08M | $8.16M | $86.61M | $24.77M |
| Pretax Profit | -$111.36M | -$90.19M | -$122.09M | -$577.97M | -$130.00M |
| Tax | $74,000.00 | $960,000.00 | $839,000.00 | $3.63M | $614,000.00 |
| Net Profit | -$111.44M | -$91.15M | -$122.93M | -$581.60M | -$130.61M |
| Profit from Continuing Operations | -$111.44M | -$91.15M | -$122.93M | -$581.60M | -$130.61M |
| Net Income to Parent Company | -$111.44M | -$91.15M | -$122.93M | -$581.60M | -$130.61M |
| Net Income to Common Stockholders | -$111.44M | -$91.15M | -$122.93M | -$581.60M | -$130.61M |
| Basic EPS | -$1.15 | -$0.94 | -$1.28 | -$6.47 | -$1.37 |
| Diluted EPS | -$1.15 | -$0.94 | -$1.28 | -$6.47 | -$1.37 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $2.56B | $2.65B | $2.73B | $2.27B | $2.27B |
| Total Current Assets | $2.29B | $2.37B | $2.45B | $1.99B | $1.99B |
| Cash and Cash Equivalents & Short-Term Investments | $2.27B | $2.36B | $2.44B | $1.98B | $1.98B |
| -Cash and Cash Equivalents | $192.03M | $291.34M | $423.31M | $347.56M | $347.56M |
| -Short Term Investments | $2.08B | $2.07B | $2.02B | $1.63B | $1.63B |
| Other Current Assets | $12.53M | $7.42M | $6.58M | $9.84M | $9.84M |
| Total Non-Current Assets | $271.33M | $279.00M | $277.46M | $279.57M | $279.57M |
| Net PPE | $226.91M | $233.66M | $240.85M | $247.58M | $247.58M |
| -Gross PPE | $330.71M | $333.25M | $336.19M | $338.63M | $338.63M |
| -Accumulated Depreciation | -$103.80M | -$99.59M | -$95.34M | -$91.05M | -$91.05M |
| Investments and Advances | $4.02M | – | – | – | – |
| -Available for Sale Securities | $4.02M | – | – | – | – |
| Other Non-Current Assets | $40.41M | $45.34M | $36.61M | $32.00M | $32.00M |
| Total Liabilities | $908.34M | $904.22M | $911.26M | $343.43M | $343.43M |
| Total Current Liabilities | $140.96M | $132.90M | $136.29M | $149.12M | $149.12M |
| Payables | $20.72M | $11.80M | $14.29M | $12.25M | $12.25M |
| -Accounts Payable | $20.59M | $11.31M | $13.65M | $11.14M | $11.14M |
| -Total Tax Payable | $132,000.00 | $494,000.00 | $638,000.00 | $1.11M | $1.11M |
| Current Accrued Expenses | $82.02M | $70.28M | $74.93M | $89.41M | $89.41M |
| Short-Term Debt and Capital Lease Obligation | $18.68M | $18.65M | $18.61M | $18.58M | $18.58M |
| -Current Capital Lease Obligation | $18.68M | $18.65M | $18.61M | $18.58M | $18.58M |
| Current Deferred Liabilities | $2.55M | $15.19M | $15.34M | $15.77M | $15.77M |
| Other Current Liabilities | $17.00M | $16.98M | $13.11M | $13.11M | $13.11M |
| Total Non-Current Liabilities | $767.38M | $771.32M | $774.98M | $194.31M | $194.31M |
| Long Term Debt and Capital Lease Obligation | $761.15M | $765.10M | $769.03M | $188.17M | $188.17M |
| -Long Term Debt | $586.93M | $586.20M | $585.47M | – | – |
| -Long Term Capital Lease Obligation | $174.21M | $178.90M | $183.56M | $188.17M | $188.17M |
| Other Non-Current Liabilities | $6.24M | $6.22M | $5.95M | $6.14M | $6.14M |
| Total Equity | $1.65B | $1.75B | $1.81B | $1.92B | $1.92B |
| Stockholders' Equity | $1.65B | $1.75B | $1.81B | $1.92B | $1.92B |
| Capital Stock | $3.15M | $3.13M | $3.12M | $3.09M | $3.09M |
| -Common Stock | $3.15M | $3.13M | $3.12M | $3.09M | $3.09M |
| Additional Paid-In Capital | $3.93B | $3.91B | $3.88B | $3.86B | $3.86B |
| Retained Earnings | -$2.27B | -$2.16B | -$2.07B | -$1.95B | -$1.95B |
| Less: Treasury Stock | -$60,000.00 | -$60,000.00 | -$60,000.00 | -$60,000.00 | -$60,000.00 |
| Gains/Losses Not Affecting Retained Earnings | -$14.08M | -$4.63M | -$1.94M | $4.82M | $4.82M |
| Receivables | – | – | – | $0.00 | $0.00 |
| -Accounts Receivable | – | – | – | $0.00 | $0.00 |
| Non-Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$89.68M | -$83.50M | -$108.90M | -$345.01M | -$92.55M |
| Net cash flow from continuing operations | -$89.68M | -$83.50M | -$108.90M | -$345.01M | -$92.55M |
| Net Income from Continuing Operations | -$111.44M | -$91.15M | -$122.93M | -$581.60M | -$130.61M |
| Depreciation & Depletion & Amortization | $4.24M | $4.28M | $4.32M | $19.48M | $5.66M |
| Other Non-Cash Items | -$2.60M | -$10.24M | $8.80M | $72.73M | -$8.31M |
| Change in Working Capital | $2.15M | -$3.70M | -$15.41M | $71.88M | $22.64M |
| -Change in Receivables | $0.00 | $0.00 | $0.00 | $25.00M | $0.00 |
| -Change in Prepaid Assets | -$4.18M | -$841,000.00 | -$247,000.00 | $3.34M | $3.85M |
| -Change in Payables and Accrued Expense | $20.62M | -$5.31M | -$13.02M | $44.89M | $4.42M |
| -Change in Other Current Liabilities | $32,000.00 | $4.15M | -$199,000.00 | $4.26M | $13.55M |
| -Change In Other Working Capital | -$14.32M | -$1.70M | -$1.95M | -$5.61M | $810,000.00 |
| Net cash flow from investing | -$14.09M | -$55.66M | -$410.74M | -$31.81M | $37.20M |
| Net Cash Flow from Continuing Investing Activities | -$14.09M | -$55.66M | -$410.74M | -$31.81M | $37.20M |
| Net PPE Purchase and Sale | -$414,000.00 | -$648,000.00 | -$504,000.00 | -$914,000.00 | -$517,000.00 |
| Net Intangibles Purchase and Sale | $825,000.00 | – | – | -$25.00M | $0.00 |
| Net Investment Purchase and Sale | -$14.50M | -$52.54M | -$410.24M | -$5.89M | $37.72M |
| Financing Cash Flow | $4.45M | $7.18M | $591.91M | $426.03M | $116.41M |
| Net Cash Flow from Continuing Financing Activities | $4.45M | $7.18M | $591.91M | $426.03M | $116.41M |
| Net Common Stock Issuance | $0.00 | – | – | $398.09M | $111.49M |
| Net Preferred Stock Issuance | $0.00 | $0.00 | $600.00M | – | – |
| Proceeds from Stock Option Exercised | $4.45M | $8.30M | $6.16M | $27.94M | $4.92M |
| Net Other Financing Charges | $0.00 | -$400,000.00 | -$14.25M | – | – |
| Ending Cash Balance | $200.03M | $299.34M | $431.31M | $359.08M | $359.08M |
| Net Change in Cash | -$99.32M | -$131.98M | $72.27M | $49.21M | $61.06M |
| Beginning Cash Balance | $299.34M | $431.31M | $359.08M | $309.78M | $298.02M |
| Effect of Exchange Rate Changes | $6,000.00 | $6,000.00 | -$32,000.00 | $95,000.00 | $1,000.00 |
| Free Cash Flow | -$89.27M | -$86.62M | -$109.40M | -$370.93M | -$93.07M |
No comments yet — be the first to weigh in on CRSP.
Sign in to join the discussion.